Cipla Limited submitted a regulatory disclosure to the BSE Ltd. and National Stock Exchange of India Ltd. pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The disclosure concerns a routine current Good Manufacturing Practices (cGMP) inspection conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. InvaGen is identified as a wholly-owned subsidiary of Cipla Limited. The facility is located in Hauppauge, Long Island, New York, USA.
The inspection period was from 19th October, 2026 to 22nd October, 2026 (ET).
The key outcome of the inspection is that it concluded with zero Form 483 observations. A Form 483 is issued by the USFDA at the conclusion of an inspection if investigators observe any conditions that may constitute violations of the Food Drug and Cosmetic Act.
The letter was signed by Rajendra Chopra, Company Secretary, and was prepared by Chirag Hotchandani.